Camber1jpj (Camber1jpg)
Tadalafil Tablet, Film Coated
Product Images NDC 50090-4660
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4660). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image (Lbl500904660)
Label for Tadalafil 5 mg film-coated tablets by A-S Medication Solutions. The label shows product number 6879-0, lot number 41431, and storage instructions to keep the product at 68 to 77 degrees Fahrenheit. The package contains 90 tablets. The label includes the NDC 50090-4660-0 and a QR code for dosage instructions.*
Tadalafilfigure1.jpg (Tadalafilfigure1)
A set of four line graphs showing the difference in blood pressure measurements (systolic and diastolic) between Tadalafil and placebo over time in hours. The graphs separately display standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure, with error bars indicating variability at each time point up to 96 hours.*
Tadalafilfigure2.jpg (Tadalafilfigure2)
Two line graphs show the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours. The top graph depicts standing systolic blood pressure changes, and the bottom graph depicts supine systolic blood pressure changes, both measured in mmHg at various time points post-dose (0 to 24 hours).*
Tadalafilfigure4.jpg (Tadalafilfigure4)
A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo combined with doxazosin at different times (08:00 and 20:00). It compares 20 mg tadalafil plus 8 mg doxazosin versus placebo plus 8 mg doxazosin, illustrating blood pressure trends over time.*
Tadalafilfigure5.jpg (Tadalafilfigure5)
A plasma tadalafil concentration versus time graph comparing three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg tadalafil following five consecutive days of administration. The x-axis represents time in hours, and the y-axis shows plasma tadalafil concentration in µg/L, with data points and error bars illustrating variability.*
Tadalfilfigure6.jpg (Tadalafilfigure6)
A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks; the y-axis shows change from baseline. The graph includes statistical significance indication (p<0.01).*
Tadalafilfigure7.jpg (Tadalafilfigure7)
Line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the score change. Tadalafil 5 mg demonstrates a greater decrease in score compared to placebo, with statistical significance indicated at select time points.*
Tadalafilfigure8 (Tadalafilfigure8)
A line graph showing the least squares mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride. The y-axis represents the LS mean change, and the x-axis shows weeks of therapy at 0, 4, 12, and 26 weeks. The graph compares treatment differences with statistical annotations for significance.*
Tadalfilfigure9.jpg (Tadalafilfigure9)
A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil and placebo. The x-axis represents duration of treatment in weeks, and the y-axis indicates change from baseline in IPSS total score. Tadalafil shows a greater decrease in score compared to placebo, with significant differences noted (p<0.01).*
Tadalafilstructure.jpg (Tadalafilstructure)
Chemical structure of Tadalafil depicting its molecular framework, including fused rings and functional groups as shown in the labeled diagram.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
